Tectonic Therapeutic, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TECX research report →
Range $75 – $81
Price Chart
About the company
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines.
- CEO
- Alise S. Reicin
- IPO
- 2018
- Employees
- 60
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on TECX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $437.20M
- P/E
- -5.07
- PEG
- 0.39
- P/S
- 0.00
- P/B
- 1.96
- EV/EBITDA
- -2.56
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.26%
- ROIC
- -41.59%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-84,036,000
- Net Income
- $-74,151,000-27.9%
- EPS
- $-4.05-3.1%
- OCF Growth
- -1.7%
- FCF Growth
- -1.8%
- 52W High
- $39.53
- 52W Low
- $15.45
- 50D MA
- $29.63
- 200D MA
- $28.06
- Beta
- 0.22
- RSI (14)
- 36
- Avg Volume
- 219.63K
No earnings-call transcripts are available for TECX yet.
- Free Float
- 50.2%
- Shares Outstanding
- 18.87M
- Float Shares
- 9.48M
of shares held by institutions
116 13F filers
Buy/sell ratio 0.70. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 2.83M | ▲ 13.88K |
| Tcg Crossover Management, LLC | 1.20M | 0 |
| Abrdn PLC | 1.14M | 0 |
| Blackrock, Inc. | 862.59K | ▲ 2.24K |
| First Light Asset Management, LLC | 800.73K | ▲ 152.98K |
| Baker Bros. Advisors LP | 607.79K | 0 |
| 5am Venture Management, LLC | 606.66K | 0 |
| Vanguard Group Inc | 599.90K | ▲ 30.42K |
| Braidwell LP | 596.90K | ▼ 250.25K |
| Vanguard Capital Management LLC | 488.81K | ▲ 15.27K |
| Vestal Point Capital, LP | 425.00K | ▲ 97.00K |
| Bollard Group LLC | 302.95K | 0 |
Held by 131 ETFs
Biggest fund positions in TECX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | Lochner Daniel | other | 520 |
| Sep 25, 26 | McNamara Peter | other | 444 |
| Sep 30, 26 | McNamara Peter | sell | 536 |
| Sep 25, 26 | Ruddy Marcella K. | other | 525 |
| Sep 25, 26 | REICIN ALISE | other | 1,545 |
| Sep 25, 26 | Schwabish Marc | other | 411 |
| Sep 3, 26 | Schwabish Marc | other | 17,750 |
| Sep 3, 26 | McNamara Peter | other | 21,000 |
| Sep 3, 26 | Lochner Daniel | other | 24,250 |
| Sep 3, 26 | Ruddy Marcella K. | other | 24,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TECX coverage
Recent articles, reports, and earnings notes.
No research on TECX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TECX report →Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
globenewswire.com · Sep 29
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts
defenseworld.net · Sep 26
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
globenewswire.com · Sep 3
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
seekingalpha.com · Sep 2
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Aug 6
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
globenewswire.com · Jun 10
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
globenewswire.com · Jun 10
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.